Demand for weight-loss medications sold under brand names such as Ozempic and Zepboundthe first US Food and Drug Administration-approved medication for moderate-to-severe obstructive sleep apnea (OSA) and obesitycontinues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease, or obesity
Briefly, Caco-2 cells were seeded in 96-well plates and allowed to grow in culture media for three weeks, feeding at 2-day intervals
Notably, the risk appeared higher in trials studying weight loss indications, with higher doses, and with longer duration of treatment
The most common patterns in claims involve: A serious complication (pancreatitis, gallbladder disease, severe gastroparesis, or vision loss) where the patient was never warned of the risk or counselled on the warning signs A serious complication in a patient with a contraindication that was identifiable from the medical history but was not asked about A patient who reported significant symptoms (severe vomiting, persistent abdominal pain, neurological changes) and was not assessed in person or referred onward in a timely way A pregnancy that occurred in a patient who was not counselled about the need to stop semaglutide before conceiving What patients should do If you believe that improper prescribing of Ozempic, Wegovy, or another GLP-1 drug contributed to a serious injury or death, the most useful first step is to obtain a complete copy of the medical records: the prescribing physicians chart, any online platforms records, the pharmacys records, and any subsequent treating providers chart
The rubber stopper should be cleaned with alcohol before each access, and sterile technique should be maintained throughout the withdrawal process
3B, Supplementary Fig
